nanotech-investing Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
nanotech-investing Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
nanotech-investing Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
nanotech-investing Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
nanotech-investing Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
